

30 June 2023

Tender results

Pharmac has resolved to award tenders for Principal Supply Status for some products included in the 2021/22 Invitation to Tender, dated 1 November 2021 and the 2022/23 Invitation to Tender, dated 31 October 2022.

Some of the Pharmaceuticals that will be delisted when the period of Principal Supply Status commences may be subject to existing listing contracts with Pharmac. Suppliers of Pharmaceuticals that are subject to such contracts should continue to supply their Pharmaceuticals under those contracts. Pharmac will continue to subsidise those Pharmaceuticals accordingly until such time as those Pharmaceuticals are delisted.

Notification of Product Changes (NOPC) forms

Please note that for any changes (price change, pack size change, new listing etc) to be effective in the Pharmaceutical Schedule (including Section H), suppliers are required to submit a Notification of Product Changes (NOPC) form to Pharmac, the Pharmacy Guild and the NZULM by:

- **For new listings**, by 4pm on the 12th of July 2023 or the 5th of the month prior to listing, whichever is earlier
- **For price changes**, by 4pm on the 12th of the month prior to the date of subsidy change

Pharmac cannot list a product (and Pharmacies cannot claim) without this information. More information about this process, and a copy of the NOPC form can be found on our website – <https://pharmac.govt.nz/medicine-funding-and-supply/make-an-application/pharmconnect-make-a-medicine-funding-application/process-for-notification-of-product-changes/>

Suppliers are required to ensure that a Pharmacode has been obtained from the Pharmacy Guild of New Zealand (<http://www.pgnz.org.nz/about-us-1/Pharmacode>) and that a CTPP code has been obtained from the New Zealand Universal List of Medicines (<http://www.nzulm.org.nz/sponsors>). Pharmacodes and CTPP codes must be provided to Pharmac by the 5th of the month prior to the date of listing, or 10 business days following the market notification date (whichever is earliest). Pharmac cannot list a product (and Pharmacies cannot claim) without the correct Pharmacode.

2021/22 Tender – Principal Supply Status applies until 30 June 2025

Community Pharmaceutical tenders – Section B of the Pharmaceutical Schedule

The decisions were as follows (amendments to presentation in **bold**):

1. *Tenders awarded to pharmaceuticals where at least one other brand is listed.*

Chemical name	Presentation; Pack size and type	Current pack price	New pack price	Principal Supply brand (Supplier)	Listing date	Principal Supply date	Brand (Supplier) affected by delisting
Budesonide	Cap modified-release 3 mg; 90 capsule bottle	\$166.50	\$87.60	Budesonide Te Arai (Te Arai)	1 November 2023	1 April 2024	Entocort CIR (Pharmacodes 2272547 and 2536528) (Chiesi)

Hospital Pharmaceutical tenders – Section H of the Pharmaceutical Schedule

The decisions were as follows (amendments to presentation in **bold**):

2. *Tenders awarded to Pharmaceuticals where no other brand is listed.*

Chemical name	Presentation; Pack size and type	Current pack price	New pack price	Principal Supply brand (Supplier)	DV limit	Date of price change	Principal Supply date
Budesonide	Cap modified-release 3 mg; 90 capsule bottle	\$166.50	\$87.60	Budesonide Te Arai (Te Arai)	5%	1 November 2023	1 April 2024

3. *Tenders awarded to currently listed Pharmaceuticals where at least one other brand is listed.*

Chemical name	Presentation; Pack size and type	Current pack price	New pack price	Principal Supply brand (Supplier)	DV limit	Listing date	Principal Supply date	Brand (Supplier) affected by delisting
Daptomycin	Inj 500 mg vial; 1 vial pack	\$243.52	\$115.36	Daptomycin Dr Reddy's (Dr Reddy's)	5%	1 August 2023	1 January 2024	Cubicin (MSD)

2022/23 Tender – Principal Supply Status applies until 30 June 2026

Community Pharmaceutical tenders – Section B of the Pharmaceutical Schedule

The decisions were as follows:

4. Tenders awarded to pharmaceuticals where at least one other brand is listed

Chemical name	Presentation; Pack size and type	Current pack price	New pack price	Principal Supply brand (Supplier)	Listing date	Principal Supply date	Brand (Supplier) affected by delisting
Allopurinol	Tab 100 mg; 1000 tablet bottle	\$11.47 (500 tablet bottle)	\$17.99	Ipca-Allopurinol (Miro)	1 January 2024	1 June 2024	DP-Allopurinol (Douglas)
Allopurinol	Tab 300 mg; 500 tablet bottle	\$28.57	\$22.50	Ipca-Allopurinol (Miro)	1 January 2024	1 June 2024	DP-Allopurinol (Douglas)
Donepezil hydrochloride ¹	Tab 5 mg; 84 tablet blister pack	\$4.34 (90 tablet blister pack)	\$3.70	Ipca-Donepezil	1 January 2024	1 June 2024	Donepezil-Rex (Rex Medical)
Donepezil hydrochloride ¹	Tab 10 mg; 84 tablet blister pack	\$6.64 (90 tablet blister pack)	\$5.50	Ipca-Donepezil	1 January 2024	1 June 2024	Donepezil-Rex (Rex Medical)
Febuxostat	Tab 80 mg; 28 tablet blister pack	\$20.00	\$4.73	Febuxostat (Teva)	1 January 2024	1 June 2024	Febuxostat multichem (Multichem)
Febuxostat	Tab 120 mg; 28 tablet blister pack	\$20.00	\$11.78	Febuxostat (Teva)	1 January 2024	1 June 2024	Febuxostat multichem (Multichem)

¹Brand switch fee of \$4.50 is payable for this product from 1 June 2024 to 31 August 2024

Hospital Pharmaceutical tenders – Section H of the Pharmaceutical Schedule.

5. Tenders awarded to pharmaceuticals where at least one other brand is listed.

Chemical name	Presentation; Pack size and type	Current pack price	New pack price	Principal Supply brand (Supplier)	DV limit	Listing date	Principal Supply date	Brand (Supplier) affected by delisting
Allopurinol	Tab 100 mg; 1000 tablet bottle	\$11.47 (500 tablet bottle)	\$17.99	Ipca-Allopurinol (Miro)	5%	1 January 2024	1 June 2024	DP-Allopurinol (Douglas)
Allopurinol	Tab 300 mg; 500 tablet bottle	\$28.57	\$22.50	Ipca-Allopurinol (Miro)	5%	1 January 2024	1 June 2024	DP-Allopurinol (Douglas)
Donepezil hydrochloride	Tab 5 mg; 84 tablet blister pack	\$4.34 (90 tablet blister pack)	\$3.70	Ipca-Donepezil	5%	1 January 2024	1 June 2024	Donepezil-Rex (Rex Medical)
Donepezil hydrochloride	Tab 10 mg; 84 tablet blister pack	\$6.64 (90 tablet blister pack)	\$5.50	Ipca-Donepezil	5%	1 January 2024	1 June 2024	Donepezil-Rex (Rex Medical)
Febuxostat	Tab 80 mg; 28 tablet blister pack	\$20.00	\$4.73	Febuxostat (Teva)	5%	1 January 2024	1 June 2024	Febuxostat multichem (Multichem)
Febuxostat	Tab 120 mg; 28 tablet blister pack	\$20.00	\$11.78	Febuxostat (Teva)	5%	1 January 2024	1 June 2024	Febuxostat multichem (Multichem)

Tender declines - Products where no tender is to be awarded for Principal Supply Status

Pharmac has resolved not to award tenders for Principal Supply Status for the following products listed in the:

- 2020/21 Invitation to Tender, dated 2 November 2020
- 2021/22 Invitation to Tender, dated 1 November 2021
- 2022/23 Invitation to Tender dated 31 October 2022

2020/21 Invitation to Tender

Chemical name	Line item
Baclofen	Tab 10 mg
Brimonidine tartrate with timolol maleate	Eye drops 0.2% with timolol maleate 0.5%
Carboplatin	Inj 10 per ml, 45 ml
Chlorhexidine gluconate	Mouthwash 0.2%
Hydroxychloroquine sulphate	Tab 200 mg
Lanreotide	Inj 60 mg per 0.5 ml, 0.5 ml syringe
Lanreotide	Inj 90 mg per 0.5 ml, 0.5 ml syringe
Lanreotide	Inj 120 mg per 0.5 ml, 0.5 ml syringe

Chemical name	Line item
Methotrexate	Inj 7.5 mg prefilled syringe
Methotrexate	Inj 10 mg prefilled syringe
Methotrexate	Inj 15 mg prefilled syringe
Methotrexate	Inj 20 mg prefilled syringe
Methotrexate	Inj 25 mg prefilled syringe
Methotrexate	Inj 30 mg prefilled syringe
Terlipressin	Inj 0.2 mg per ml, 5 ml
Terlipressin	Inj 1 mg per 8.5 ml ampoule

2021/22 Invitation to Tender

Chemical name	Line item
Oxybutynin	Tab 5 mg

2022/23 Invitation to Tender

Chemical name	Line item
Allopurinol (febuxostat funded without restrictions)	Tab 100 mg
Allopurinol (febuxostat funded without restrictions)	Tab 300 mg
Febuxostat (widened access)	Tab 80 mg
Febuxostat (widened access)	Tab 120 mg
Ketamine	Inj 100 mg per ml, 2 ml
Levodopa with carbidopa	Tab 100 mg with carbidopa 25 mg
Levodopa with carbidopa	Tab 250 mg with carbidopa 25 mg
Levodopa with carbidopa	Tab long-acting 200 mg with carbidopa 50 mg
Paracetamol	Inj 10 per ml, 100 ml

Chemical name	Line item
Pyridostigmine bromide	Tab 60 mg
Sacubitril with valsartan (current access)	Tab 24.3 mg with valsartan 25.7 mg
Sacubitril with valsartan (current access)	Tab 48.6 mg with valsartan 51.4 mg
Sacubitril with valsartan (current access)	Tab 97.2 mg with valsartan 102.8 mg
Sacubitril with valsartan (widened access)	Tab 24.3 mg with valsartan 25.7 mg
Sacubitril with valsartan (widened access)	Tab 48.6 mg with valsartan 51.4 mg
Sacubitril with valsartan (widened access)	Tab 97.2 mg with valsartan 102.8 mg
Timolol	Eye drops 0.5%, gel forming

Tender decisions on all products included in the 2020/21 Invitation to Tender have now all been announced. For products included in the 2021/22 and 2022/2023 Invitation to Tender where no announcement has yet been made, either a decision is still pending subject to Pharmac Board (or its delegate) approval. We will keep you informed of any updates regarding such tender products as decisions are made.

If you have any queries regarding this notification, please contact Pharmac on 0800 66 00 50.